

=> d his

(FILE 'HOME' ENTERED AT 10:22:40 ON 11 MAY 2005)

FILE 'CAPLUS' ENTERED AT 10:34:24 ON 11 MAY 2005

L1 1 S US6586455/PN  
SELECT L1 1 RN  
L2 58943 S E1-E9

FILE 'REGISTRY' ENTERED AT 10:38:36 ON 11 MAY 2005

L3 1 S 110-00-9/RN  
SET NOTICE 1 DISPLAY  
SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 10:38:54 ON 11 MAY 2005

L4 1 S 153559-49-0/RN  
SET NOTICE 1 DISPLAY  
SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 10:41:23 ON 11 MAY 2005

L5 1 S 153559-76-3/RN  
SET NOTICE 1 DISPLAY  
SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 10:42:30 ON 11 MAY 2005

L6 1 S 122320-73-4/RN  
SET NOTICE 1 DISPLAY  
SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 10:44:35 ON 11 MAY 2005

L7 1 S 111025-46-8/RN  
SET NOTICE 1 DISPLAY  
SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 10:48:22 ON 11 MAY 2005

L8 1 S 97322-87-7/RN  
SET NOTICE 1 DISPLAY  
SET NOTICE LOGIN DISPLAY

FILE 'CAPLUS' ENTERED AT 10:49:24 ON 11 MAY 2005

L9 3215 S L8 OR L7 OR L6 OR NOSCAL OR REZULIN OR ROMGLIZONE OR TROGLITA  
L10 87 S L9(L) ((BREAST OR LEUKEM? OR COLON? OR PROSTATE) (S) (CANCER? OR  
L11 0 S L10 NOT PY>=1996  
L12 43 S L10 NOT PY>=2003

=> s 19(1)(breast or leukem? or colon? or prostate or cancer? or neoplas? or tumor? or carcino?  
or ?sarcoma#)

TRUNCATION COMBINATION NOT VALID '?SARCOMA#'

Simultaneous left and right truncation is not possible for this  
combination of truncation symbols. For more information about  
truncation in the current file, enter "HELP TRUNCATION".

=> s 19(1)(breast or leukem? or colon? or prostate or cancer? or neoplas? or tumor? or carcino?  
or ?sarcoma)

60700 BREAST  
505 BREASTS  
60881 BREAST  
(BREAST OR BREASTS)  
94650 LEUKEM?  
137357 COLON?  
40825 PROSTATE  
1255 PROSTATES  
40931 PROSTATE  
(PROSTATE OR PROSTATES)  
257906 CANCER?  
407959 NEOPLAS?  
389645 TUMOR?  
220528 CARCINO?

371  
369.

45163 ?SARCOMA

L13 428 L9(L) (BREAST OR LEUKEM? OR COLON? OR PROSTATE OR CANCER? OR  
NEOPLAS? OR TUMOR? OR CARCINO? OR ?SARCOMA)

=> s l13 not py>=2000

5429777 PY>=2000

L14 55 L13 NOT PY>=2000

=> s l13 not py>=2004

1528329 PY>=2004

L15 294 L13 NOT PY>=2004

=> d ibib


```
=> s us6646008/pn
L1      1 US6646008/PN
```

```
=> select l1
ENTER ANSWER NUMBER OR RANGE (1-):1
ENTER DISPLAY CODE (TI) OR ?:rn
E1 THROUGH E11 ASSIGNED
```

```
=> s e1-e11
      3141 41598-07-6/BI
      247 60203-57-8/BI
      164 102121-60-8/BI
      9575 110-00-9/BI
      160 153559-49-0/BI
      103 153559-76-3/BI
      1331 5300-03-8/BI
      15402 59-67-6/BI
      30987 65-85-0/BI
      172 87893-54-7/BI
      501 87893-55-8/BI
L2    60305 (41598-07-6/BI OR 60203-57-8/BI OR 102121-60-8/BI OR 110-00-9/BI
           OR 153559-49-0/BI OR 153559-76-3/BI OR 5300-03-8/BI OR 59-67-6/
           BI OR 65-85-0/BI OR 87893-54-7/BI OR 87893-55-8/BI)
```

L7 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 111025-46-8 REGISTRY  
 CN 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-  
 (9CI) (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-  
 , (±)-  
 OTHER NAMES:  
 CN 5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione  
 CN Pioglitazone  
 CN U 72107  
 FS 3D CONCORD  
 DR 105355-27-9, 198077-89-3  
 MF C19 H20 N2 O3 S  
 CI COM  
 SR US Adopted Names Council (USAN)  
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*,  
 BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB,  
 CEN, CHEMCATS, CIN, CSCHM, DDFU, DIOGENES, DRUGU, EMBASE, IMSDRUGNEWS,  
 IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK\*, PATDPASPC, PHAR, PROMT,  
 PROUSDDR, PS, RTECS\*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL  
 (\*File contains numerically searchable property data)  
 Other Sources: WHO  
 DT.CA Caplus document type: Book; Conference; Dissertation; Journal; Patent  
 RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);  
 MSC (Miscellaneous); PREP (Preparation); PROC (Process); PRP  
 (Properties); RACT (Reactant or reagent); USES (Uses)  
 RLD.P Roles for non-specific derivatives from patents: ANST (Analytical  
 study); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological  
 study); PREP (Preparation); PROC (Process); PRP (Properties); RACT  
 (Reactant or reagent); USES (Uses)  
 RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological  
 study); PREP (Preparation); PRP (Properties); USES (Uses)

PAGE 1-A



*Compound is class 5*

|  
Et

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


934 REFERENCES IN FILE CA (1907 TO DATE)

9 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA


944 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L6 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 122320-73-4 REGISTRY  
 CN 2,4-Thiazolidinedione, 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN 5-[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione  
 CN 5-[[4-[2-(N-Methyl-N-(2-pyridyl)amino)ethoxy]phenyl]methyl]thiazolidine-2,4-dione  
 CN BRL 49653  
 CN Rosiglitazone  
 CN Rosiglitazone  
 FS 3D CONCORD  
 MF C18 H19 N3 O3 S  
 CI COM  
 SR CA  
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CEN, CHEMCATS, CIN, CSChem, DDFU, DIOGENES, DRUGU, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK\*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS\*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL  
 (\*File contains numerically searchable property data)  
 DT.CA Caplus document type: Conference; Dissertation; Journal; Patent  
 RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)  
 RLD.P Roles for non-specific derivatives from patents: ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); FORM (Formation, nonpreparative); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)  
 RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological study); PREP (Preparation); PRP (Properties)

PAGE 1-A



*Instant  
Compound  
in clar 5  
formal.*



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1126 REFERENCES IN FILE CA (1907 TO DATE)


10 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

1136 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L8 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN  
 RN 97322-87-7 REGISTRY  
 CN 2,4-Thiazolidinedione, 5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl)methyl]- (9CI) (CA INDEX NAME)  
 OTHER NAMES:  
 CN CI 991  
 CN CS 045  
 CN GR 92132X  
 CN Noscal  
 CN Rezulin  
 CN Romglizone  
 CN Troglitazone  
 FS 3D CONCORD  
 DR 259223-65-9  
 MF C24 H27 N O5 S  
 CI COM  
 SR CA  
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*,  
 BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB,  
 CEN, CHEMCATS, CIN, CSCHM, DDFU, DIOGENES, DRUGU, EMBASE, IMSDRUGNEWS,  
 IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK\*, PHAR, PROMT, PROUSDDR, PS,  
 RTECS\*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL  
 (\*File contains numerically searchable property data)

Other Sources: WHO

DT.CA Caplus document type: Conference; Dissertation; Journal; Patent  
 RL.P Roles from patents: ANST (Analytical study); BIOL (Biological study);  
 PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or  
 reagent); USES (Uses)  
 RLD.P Roles for non-specific derivatives from patents: ANST (Analytical  
 study); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological  
 study); MSC (Miscellaneous); PREP (Preparation); PROC (Process); PRP  
 (Properties); RACT (Reactant or reagent); USES (Uses)  
 RLD.NP Roles for non-specific derivatives from non-patents: BIOL (Biological  
 study); FORM (Formation, nonpreparative); PROC (Process); USES (Uses)



*compound in  
claim 5*

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*


1372 REFERENCES IN FILE CA (1907 TO DATE)  
 14 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 1379 REFERENCES IN FILE CAPLUS (1907 TO DATE)



L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 153559-76-3 REGISTRY  
CN 3-Pyridinecarboxylic acid, 6-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)cyclopropyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN AGN 192620  
CN ALRT 268  
CN CD 3127  
CN LG 100268  
CN LG 268  
CN LGD 100268  
CN LGD 1268  
FS 3D CONCORD  
DR 197730-94-2, 262615-35-0, 263723-53-1, 309956-42-1  
MF C24 H29 N O2  
SR CA  
LC STN Files: ADISNEWS, AGRICOLA, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CHEMCATS, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, RTECS\*, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)  
DT.CA Caplus document type: Journal; Patent  
RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)  
RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); PREP (Preparation); USES (Uses)  
RL.NP Roles from non-patents: BIOL (Biological study); PREP (Preparation); PROC (Process); PRP (Properties); USES (Uses)



*Compound  
in Jan 12*

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

103 REFERENCES IN FILE CA (1907 TO DATE)  
2 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
103 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L4 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2005 ACS on STN  
RN 153559-49-0 REGISTRY  
CN Benzoic acid, 4-[1-(5,6,7,8-tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]- (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Bexarotene  
CN LG 100069  
CN LG 1069  
CN LG 69  
CN LG 69 (retinoid)  
CN LGD 1069  
CN RO 26-4455  
CN SR 11247  
CN Targret  
CN Targretin  
CN Targretyn  
CN Targrexin  
FS 3D CONCORD  
MF C24 H28 O2  
SR CA

LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CASREACT, CIN, DIOGENES, EMBASE, IMSDRUGNEWS, IMSPATENTS, IMSRESEARCH, IPA, MRCK\*, PATDPASPC, PHAR, PROMT, PROUSDDR, PS, RTECS\*, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)


DT.CA Caplus document type: Journal; Patent

RL.P Roles from patents: BIOL (Biological study); PREP (Preparation); PROC (Process); RACT (Reactant or reagent); USES (Uses)

RLD.P Roles for non-specific derivatives from patents: BIOL (Biological study); USES (Uses)

RL.NP Roles from non-patents: ANST (Analytical study); BIOL (Biological study); MSC (Miscellaneous); PREP (Preparation); PROC (Process); PRP (Properties); RACT (Reactant or reagent); USES (Uses)

RLD.NP Roles for non-specific derivatives from non-patents: ANST (Analytical study)



*compound  
claim 13*

\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

162 REFERENCES IN FILE CA (1907 TO DATE)

3 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

163 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L20 ANSWER 34 OF 52 USPATFULL on STN  
AN 1999:141993 USPATFULL  
TI Methods for treating proliferative and inflammatory skin diseases  
IN Pershadsingh, Harrihar A., 404 Windsor Park Dr., Bakersfield, CA, United States 93311  
PI US 5981586 19991109  
AI US 1998-84037 19980522 (9)  
PRAI US 1997-47550P 19970523 (60)  
DT Utility  
FS Granted  
LN.CNT 732  
INCL INCLM: 514/543.000  
INCLS: 514/571.000  
NCL NCLM: 514/543.000  
NCLS: 514/571.000  
IC [6]  
ICM: A61K031-235  
ICS: A61K031-19  
EXF 514/543; 514/571  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 35 OF 52 USPATFULL on STN  
AN 1999:132827 USPATFULL  
TI Use of thiazolidinedione derivatives in the treatment of anovulation, hyperandrogenism and hirsutism  
IN Antonucci, Tammy, Thousand Oaks, CA, United States  
Lockwood, Dean, Ann Arbor, MI, United States  
Norris, Rebecca, Kewadin, MI, United States  
PA Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)  
PI US 5972944 19991026  
AI US 1998-124707 19980729 (9)  
RLI Division of Ser. No. US 1997-868608, filed on 4 Jun 1997 which is a continuation-in-part of Ser. No. US 1997-856987, filed on 15 May 1997, now patented, Pat. No. US 5874454 which is a continuation-in-part of Ser. No. US 1996-763286, filed on 10 Dec 1996, now abandoned which is a division of Ser. No. US 1995-469398, filed on 6 Jun 1995, now patented, Pat. No. US 5602133 which is a division of Ser. No. US 1994-292585, filed on 23 Aug 1994, now patented, Pat. No. US 5457109 which is a continuation-in-part of Ser. No. US 1993-122251, filed on 15 Sep 1993, now abandoned  
DT Utility  
FS Granted  
LN.CNT 1312  
INCL INCLM: 514/252.000  
INCLS: 514/256.000; 514/342.000; 514/360.000; 514/369.000  
NCL NCLM: 514/342.000  
NCLS: 514/256.000; 514/360.000; 514/369.000  
IC [6]  
ICM: A61K031-425  
EXF 514/252; 514/256; 514/342; 514/360; 514/369  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 36 OF 52 USPATFULL on STN  
AN 1999:128534 USPATFULL  
TI Method for the prevention of coronary artery spasm  
IN Kanda, Iwao, 1617 Via Margarita, Rancho Pales Verdes Estates, CA, United States 40206  
PI US 5968918 19991019  
AI US 1997-953340 19971017 (8)  
DT Utility  
FS Granted  
LN.CNT 336  
INCL INCLM: 514/176.000  
INCLS: 514/177.000; 514/178.000; 514/369.000; 514/652.000  
NCL NCLM: 514/176.000  
NCLS: 514/177.000; 514/178.000; 514/369.000; 514/652.000

IC [6]  
ICM: A61K031-58  
EXF 514/176; 514/177; 514/178; 514/652; 514/369  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 37 OF 52 USPATFULL on STN  
AN 1999:121364 USPATFULL  
TI Spiro-substituted azacycles as modulators of chemokine receptor activity  
IN Mills, Sander G., Scotch Plains, NJ, United States  
Maccoss, Malcolm, Freehold, NJ, United States  
Springer, Martin S., Westfield, NJ, United States  
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
PI US 5962462 19991005  
AI US 1997-989947 19971212 (8)  
PRAI US 1996-32735P 19961213 (60)  
US 1996-33558P 19961220 (60)  
DT Utility  
FS Granted  
LN.CNT 6786  
INCL INCLM: 514/278.000  
INCLS: 514/277.000; 546/015.000; 546/016.000; 546/017.000; 546/018.000  
NCL NCLM: 514/278.000  
NCLS: 514/277.000; 546/015.000; 546/016.000; 546/017.000; 546/018.000  
IC [6]  
ICM: A61K031-44  
ICS: A61K031-435; C07D209-54; C07D209-56  
EXF 546/17; 546/18; 514/278  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 38 OF 52 USPATFULL on STN  
AN 1999:81848 USPATFULL  
TI Use of PPAR $\gamma$  agonists for inhibition of inflammatory cytokine production  
IN Seed, Brian, Boston, MA, United States  
Jiang, Chengyu, Boston, MA, United States  
PA The General Hospital Corporation, Boston, MA, United States (U.S. corporation)  
PI US 5925657 19990720  
AI US 1997-878406 19970618 (8)  
DT Utility  
FS Granted  
LN.CNT 488  
INCL INCLM: 514/369.000  
INCLS: 514/370.000; 514/340.000; 514/366.000; 514/365.000  
NCL NCLM: 514/369.000  
NCLS: 514/340.000; 514/365.000; 514/366.000; 514/370.000  
IC [6]  
ICM: A01N043-78  
ICS: A61K031-425  
EXF 514/369; 514/370; 514/340; 514/366; 514/365  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 39 OF 52 USPATFULL on STN  
AN 1999:75638 USPATFULL  
TI Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them  
IN Lohray, Vidya Bhushan, Hyderabad, India  
Lohray, Braj Bhushan, Hyderabad, India  
Rao, Paraselli Bheema, Hyderabad, India  
Alla, Sekar Reddy, Hyderabad, India  
Ramanujam, Rajagopalan, Hyderabad, India  
Chakrabarti, Ranjan, Hyderabad, India  
PA Dr. Reddy's Research Foundation, Hyderabad, India (non-U.S. corporation)  
Reddy-Cheminor, Inc., Ridgewood, NJ, United States (U.S. corporation)  
PI US 5919782 19990706  
AI US 1997-851447 19970505 (8)  
RLI Continuation-in-part of Ser. No. US 1996-687840, filed on 26 Jul 1996,

now patented, Pat. No. US 5801173  
PRAI IN 1996-72396 19960506  
DT Utility  
FS Granted  
LN.CNT 2141  
INCL INCLM: 514/252.000  
INCLS: 514/318.000; 514/342.000; 514/369.000; 544/364.000; 546/194.000;  
546/280.000; 548/183.000  
NCL NCLM: 514/254.020  
NCLS: 514/318.000; 514/342.000; 514/369.000; 544/364.000; 546/194.000;  
546/269.700; 548/183.000  
IC [6]  
ICM: C07D417-12  
ICS: A61K031-425  
EXF 588/183; 544/364; 546/194; 546/280; 514/252; 514/318; 514/342; 514/369  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 40 OF 52 USPATFULL on STN  
AN 1999:75632 USPATFULL  
TI Substituted aminoquinolines as modulators of chemokine receptor activity  
IN Hagmann, William K., Westfield, NJ, United States  
Springer, Martin S., Westfield, NJ, United States  
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)  
PI US 5919776 19990706  
AI US 1997-993494 19971218 (8)  
DT Utility  
FS Granted  
LN.CNT 1808  
INCL INCLM: 514/159.000  
INCLS: 514/160.000; 514/161.000; 514/162.000; 514/163.000; 514/167.000  
NCL NCLM: 514/159.000  
NCLS: 514/160.000; 514/161.000; 514/162.000; 514/163.000; 514/167.000  
IC [6]  
ICM: A61K031-47  
ICS: A61K031-475; A61K031-49  
EXF 514/159; 514/160; 514/161; 514/162; 514/163; 514/167  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 41 OF 52 USPATFULL on STN  
AN 1999:53646 USPATFULL  
TI Composition, food product and uses of 3-guanidinopropionic acid  
IN Meglasson, Martin D., Kalamazoo, MI, United States  
PA Pharmacia & Upjohn Company, Kalamazoo, MI, United States (U.S. corporation)  
PI US 5900435 19990504  
WO 9303724 19930304  
AI US 1994-196250 19940224 (8)  
WO 1992-US6776 19920819  
19940224 PCT 371 date  
19940224 PCT 102(e) date  
RLI Continuation-in-part of Ser. No. US 1991-751239, filed on 26 Aug 1991  
And a continuation-in-part of Ser. No. US 1991-750559, filed on 26 Aug 1991, now abandoned  
DT Utility  
FS Granted  
LN.CNT 821  
INCL INCLM: 514/565.000  
INCLS: 514/866.000; 514/909.000; 426/330.000; 426/330.500  
NCL NCLM: 514/565.000  
NCLS: 426/330.000; 426/330.500; 514/866.000; 514/909.000  
IC [6]  
ICM: A61K031-195  
ICS: A23L001-00  
EXF 514/330; 514/369; 514/565; 514/592; 514/909; 514/866; 426/330; 426/330.5  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 42 OF 52 USPATFULL on STN  
AN 1999:40449 USPATFULL

TI Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them  
 IN Lohray, Vidya Bhushan, Hyderabad, India  
 Lohray, Braj Bhushan, Hyderabad, India  
 Bajji, Ashok Channaveerappa, Hyderabad, India  
 Alla, Sekar Reddy, Hyderabad, India  
 Ramanujam, Rajagopalan, Hyderabad, India  
 Chakrabarti, Ranjan, Hyderabad, India  
 PA Dr. Reddy's Research Foundation, Hyderabad, India (non-U.S. corporation)  
 Reddy-Cheminor, Inc., Ridgewood, NJ, United States (U.S. corporation)  
 PI US 5889032 19990330  
 AI US 1997-851448 19970505 (8)  
 PRAI IN 1996-82196 19960506  
 DT Utility  
 FS Granted  
 LN.CNT 2490  
 INCL INCLM: 514/369.000  
 INCLS: 514/255.000; 514/320.000; 514/342.000; 514/343.000; 514/364.000;  
 514/376.000; 514/414.000; 514/422.000; 544/369.000; 544/373.000;  
 544/376.000; 546/196.000; 546/269.700; 546/276.400; 548/144.000;  
 548/183.000; 548/227.000; 548/468.000; 548/525.000  
 NCL NCLM: 514/369.000  
 NCLS: 514/254.020; 514/254.030; 514/320.000; 514/342.000; 514/343.000;  
 514/364.000; 514/376.000; 514/414.000; 514/422.000; 544/369.000;  
 544/373.000; 544/376.000; 546/196.000; 546/269.700; 546/276.400;  
 548/144.000; 548/183.000; 548/227.000; 548/468.000; 548/525.000  
 IC [6]  
 ICM: A61K031-425  
 ICS: A61K031-395; C07D277-34; C07D417-02  
 EXF 514/255; 514/320; 514/342; 514/343; 514/364; 514/369; 514/376; 514/414;  
 514/422; 544/369; 544/373; 544/376; 546/196; 546/269.7; 546/276.4;  
 548/144; 548/183; 548/227; 548/468; 548/525  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 43 OF 52 USPATFULL on STN  
 AN 1999:40442 USPATFULL  
 TI Antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them  
 IN Lohray, Vidya Bhushan, Hyderabad, India  
 Lohray, Braj Bhushan, Hyderabad, India  
 Alla, Sekar Reddy, Hyderabad, India  
 Ramanujam, Rajagopalan, Hyderabad, India  
 Chakrabarti, Ranjan, Hyderabad, India  
 PA Reddy's Research Foundation, Hyderabad, India (non-U.S. corporation)  
 Reddy-Cheminor, Inc., Ridgewood, NJ, United States (U.S. corporation)  
 PI US 5889025 19990330  
 AI US 1997-851450 19970505 (8)  
 DT Utility  
 FS Granted  
 LN.CNT 1692  
 INCL INCLM: 514/326.000  
 INCLS: 514/227.800; 514/235.500; 514/236.800; 514/237.200; 514/255.000;  
 514/363.000; 514/364.000; 514/369.000; 514/376.000; 544/060.000;  
 544/133.000; 544/367.000; 546/207.000; 546/208.000; 546/209.000;  
 546/210.000; 548/142.000; 548/144.000; 548/183.000; 548/226.000  
 NCL NCLM: 514/326.000  
 NCLS: 514/227.800; 514/235.500; 514/236.800; 514/237.200; 514/249.000;  
 514/252.050; 514/255.050; 514/264.110; 514/266.100; 514/266.210;  
 514/363.000; 514/364.000; 514/369.000; 514/376.000; 544/060.000;  
 544/133.000; 544/367.000; 546/207.000; 546/208.000; 546/209.000;  
 546/210.000; 548/142.000; 548/144.000; 548/183.000; 548/226.000  
 IC [6]  
 ICM: A61K031-445  
 ICS: C07D417-10; C07D417-12  
 EXF 544/60; 544/133; 544/367; 546/207; 546/208; 546/209; 546/210; 548/142;  
 548/144; 548/183; 548/226; 514/227.8; 514/235.5; 514/236.8; 514/237.2;

514/255; 514/326; 514/363; 514/364; 514/369; 514/376  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 44 OF 52 USPATFULL on STN  
AN 1999:37111 USPATFULL  
TI Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases  
IN Lohray, Vidya Bhushan, Hyderabad, India  
Lohray, Braj Bhushan, Hyderabad, India  
Paraselli, Rao Bheema, Hyderabad, India  
PA Dr. Reddy's Research Foundation, Hyderabad, India (non-U.S. corporation)  
Reddy-Cheminor, Inc., Ridgewood, NJ, United States (U.S. corporation)  
PI US 5885997 19990323  
AI US 1996-777627 19961231 (8)  
PRAI IN 1996-115096 19960701  
DT Utility  
FS Granted  
LN.CNT 1914  
INCL INCLM: 514/256.000  
INCLS: 514/269.000; 514/258.000; 544/253.000; 544/298.000; 544/311.000;  
544/316.000  
NCL NCLM: 514/256.000  
NCLS: 514/266.200; 514/269.000; 544/253.000; 544/298.000; 544/311.000;  
544/316.000  
IC [6]  
ICM: C07D417-12  
ICS: A61K031-425  
EXF 544/253; 544/298; 544/311; 544/316; 514/256; 514/258; 514/269  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 45 OF 52 USPATFULL on STN  
AN 1999:27182 USPATFULL  
TI Glutamine: fructose-6-phosphate amidotransferase, its production and use  
IN Nishi, Kazunori, 16-1-402 Namiki 4-chome, Tsukuba, Ibaraki, Japan  
Hikichi, Yukiko, 21-2-1-504, Matsushiro 4-chome, Tsukuba, Ibaraki, Japan  
Shintani, Yasushi, 7-9-703, Kasuga 1-chome, Tsukuba, Ibaraki, Japan 305  
PI US 5876713 19990302  
AI US 1997-911445 19970812 (8)  
PRAI JP 1996-213944 19960813  
DT Utility  
FS Granted  
LN.CNT 3620  
INCL INCLM: 424/094.500  
INCLS: 514/012.000; 435/193.000  
NCL NCLM: 424/094.500  
NCLS: 435/193.000; 514/012.000  
IC [6]  
ICM: C12N009-10  
ICS: A61K038-45  
EXF 435/193; 424/94.5; 514/12  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


L20 ANSWER 46 OF 52 USPATFULL on STN  
AN 1999:24672 USPATFULL  
TI Use of thiazolidinedione derivatives in the treatment of polycystic ovary syndrome, gestational diabetes and disease states at risk for progressing to noninsulin-dependent diabetes mellitus  
IN Antonucci, Tammy, Thousand Oaks, CA, United States  
Lockwood, Dean, Ann Arbor, MI, United States  
Norris, Rebecca, Kewadin, MI, United States  
PA Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)  
PI US 5874454 19990223  
AI US 1997-856987 19970515 (8)  
DT Utility  
FS Granted  
LN.CNT 1217

INCL INCLM: 514/369.000  
INCLS: 514/342.000  
NCL NCLM: 514/369.000  
NCLS: 514/342.000  
IC [6]  
ICM: A61R031-425  
EXF 514/342; 514/369  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 47 OF 52 USPATFULL on STN  
AN 1999:4694 USPATFULL  
TI Sulfonylurea-glitazone combinations for diabetes  
IN Whitcomb, Randall Wayne, Ann Arbor, MI, United States  
PA Warner-Lambert Company, Morris Plains, NJ, United States (U.S. corporation)  
PI US 5859037 19990112  
AI US 1997-970057 19971113 (8)  
PRAI US 1997-38224P 19970219 (60)  
DT Utility  
FS Granted  
LN.CNT 1902  
INCL INCLM: 514/369.000  
INCLS: 514/593.000; 514/866.000  
NCL NCLM: 514/369.000  
NCLS: 514/593.000; 514/866.000  
IC [6]  
ICM: A61K031-425  
ICS: A61K031-175  
EXF 514/369; 514/593; 514/866  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 48 OF 52 USPATFULL on STN  
AN 1998:119160 USPATFULL  
TI Use of troglitazone and related compounds for the treatment of the climacteric symptoms  
IN Urban, Randall J., Friendswood, TX, United States  
Green, Allan, Galveston, TX, United States  
PA Board of Regents, The University of Texas System, Austin, TX, United States (U.S. corporation)  
PI US 5814647 19980929  
AI US 1997-811419 19970304 (8)  
DT Utility  
FS Granted  
LN.CNT 1525  
INCL INCLM: 514/369.000  
INCLS: 514/252.000; 514/256.000; 514/342.000; 514/360.000; 514/375.000; 514/376.000  
NCL NCLM: 514/369.000  
NCLS: 514/252.050; 514/255.050; 514/256.000; 514/342.000; 514/360.000; 514/375.000; 514/376.000  
IC [6]  
ICM: A61K031-44  
ICS: A61K031-425; A61K031-41  
EXF 514/252; 514/256; 514/342; 514/360; 514/369; 514/375; 514/376  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 49 OF 52 USPATFULL on STN  
AN 1998:98932 USPATFULL  
TI DHA-pharmaceutical agent conjugates of taxanes  
IN Shashoua, Victor E., Brookline, MA, United States  
Swindell, Charles S., Merion, PA, United States  
Webb, Nigel L., Bryn Mawr, PA, United States  
Bradley, Matthews O., Laytonsville, MD, United States  
PA Neuromedica, Inc., Conshohocken, PA, United States (U.S. corporation)  
PI US 5795909 19980818  
AI US 1996-651312 19960522 (8)  
DT Utility  
FS Granted





LN.CNT 2451  
INCL INCLM: 514/449.000  
INCLS: 514/549.000  
NCL NCLM: 514/449.000  
NCLS: 514/549.000  
IC [6]  
ICM: A61K031-335  
ICS: A61K031-22  
EXF 514/449; 514/549  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 50 OF 52 USPATFULL on STN  
AN 1998:54924 USPATFULL  
TI Treatment and prophylaxis of pancreatitis  
IN Fujiwara, Toshihiko, Ebina, Japan  
Horikoshi, Hiroyoshi, Funabashi, Japan  
Fukami, Masaharu, Yokohama, Japan  
PA Sankyo Company, Limited, Tokyo, Japan (non-U.S. corporation)  
PI US 5753681 19980519  
AI US 1997-819686 19970317 (8)  
PRAI JP 1996-61063 19960318  
JP 1996-250201 19960920

DT Utility  
FS Granted

LN.CNT 1149  
INCL INCLM: 514/337.000  
INCLS: 514/369.000; 514/370.000  
NCL NCLM: 514/337.000  
NCLS: 514/369.000; 514/370.000  
IC [6]  
ICM: A61K031-44  
ICS: A61K031-425  
EXF 514/337; 514/369; 514/370  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.



L20 ANSWER 51 OF 52 USPATFULL on STN  
AN 97:12471 USPATFULL  
TI Use of thiazolidinedione derivatives and related antihyperglycemic  
agents in the treatment of disease states at risk for progressing to  
noninsulin-dependent diabetes mellitus  
IN Antonucci, Tammy, Meguon, WI, United States  
Lockwood, Dean, Ann Arbor, MI, United States  
Norris, Rebecca, Kewadin, MI, United States  
PA Warner-Lambert Company, Morris Plains, NJ, United States (U.S.  
corporation)  
PI US 5602133 19970211  
AI US 1995-469398 19950606 (8)  
RLI Division of Ser. No. US 1994-292585, filed on 23 Aug 1994, now patented,  
Pat. No. US 5457109 which is a continuation-in-part of Ser. No. US  
1993-122251, filed on 15 Sep 1993, now abandoned

DT Utility  
FS Granted

LN.CNT 1639  
INCL INCLM: 514/252.000  
INCLS: 514/256.000; 514/342.000; 514/360.000; 514/369.000  
NCL NCLM: 514/254.020  
NCLS: 514/255.050; 514/256.000; 514/342.000; 514/360.000; 514/369.000  
IC [6]  
ICM: A61K031-425  
ICS: A61K031-41; A61K031-44; A61K031-42  
EXF 514/252; 514/256; 514/342; 514/360; 514/369  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L20 ANSWER 52 OF 52 USPATFULL on STN  
AN 95:90533 USPATFULL  
TI Use of thiazolidinedione derivatives and related antihyperglycemic  
agents in the treatment of disease states at risk for progressing to  
noninsulin-dependent diabetes mellitus

IN Antonucci, Tammy, Mequon, WI, United States  
Lockwood, Dean, Ann Arbor, MI, United States  
Norris, Rebecca, Kewadin, MI, United States  
PA Warner-Lambert Company, Morris Plains, NJ, United States (U.S.  
corporation)  
PI US 5457109 19951010  
AI US 1994-292585 19940823 (8)  
RLI Continuation-in-part of Ser. No. US 1993-122251, filed on 15 Sep 1993,  
now abandoned  
DT Utility  
FS Granted  
LN.CNT 1416  
INCL INCLM: 514/252.000  
INCLS: 514/256.000; 514/342.000; 514/360.000; 514/309.000  
NCL NCLM: 514/253.100  
NCLS: 514/254.020; 514/256.000; 514/342.000; 514/360.000; 514/369.000  
IC [6]  
ICM: A61K031-425  
ICS: A61K031-41; A61K031-44; A61K031-42  
EXF 514/252; 514/256; 514/342; 514/360; 514/369  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 13:29:57 ON 11 MAY 2005)

FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 13:30:06 ON 11 MAY 2005

FILE 'CAPLUS' ENTERED AT 13:30:46 ON 11 MAY 2005

L1 0 S S 122320-73-4/RN  
L2 1131 S 122320-73-4/RN  
L3 941 S 111025-46-8/RN  
L4 1375 S 97322-87-7/RN  
L5 3214 S L2 OR L3 OR L4 OR NOSCAL OR REZULIN OR ROMGLIZONE OR TROGLIT  
L6 415 S L5(L) ( LEUKEM? OR CANCER? OR NEOPLAS? OR TUMOR? OR CARCINO? O  
L7 4 S L6 NOT PY>=1997

FILE 'MEDLINE, EMBASE, BIOSIS' ENTERED AT 13:36:14 ON 11 MAY 2005

L8 11 S L7  
L9 5 DUP REM L8 (6 DUPLICATES REMOVED)

FILE 'PROMT, IMSRESEARCH, IMSPRODUCT' ENTERED AT 13:43:06 ON 11 MAY 2005

FILE 'PROMT, IMSRESEARCH, IMSPRODUCT' ENTERED AT 13:46:45 ON 11 MAY 2005

L10 1603 S NOSCAL OR REZULIN OR ROMGLIZONE OR TROGLITAZONE OR PIOGLITAZO  
L11 288 S L10(L) ( LEUKEM? OR CANCER? OR NEOPLAS? OR TUMOR? OR CARCINO?  
L12 288 S L10(L) ( LEUKEM? OR CANCER? OR NEOPLAS? OR TUMOR? OR CARCINO?  
L13 12 S L12 NOT PY>=1996  
L14 31 S L12 NOT PY>=1997  
L15 31 DUP REM L14 (0 DUPLICATES REMOVED)

FILE 'CAPLUS' ENTERED AT 13:57:50 ON 11 MAY 2005

L16 162 S 153559-49-0/RN

FILE 'REGISTRY' ENTERED AT 13:58:37 ON 11 MAY 2005

L17 1 S 153559-49-0/RN  
L18 1 S 153559-76-3/RN

FILE 'CAPLUS' ENTERED AT 13:59:40 ON 11 MAY 2005

L19 259 S L17 OR L18 OR LG(W)100268 OR LGD(W)1268 OR LG(W)268 OR LG  
L20 81 S L19(L) ( LEUKEM? OR CANCER? OR NEOPLAS? OR TUMOR? OR CARCINO?  
L21 4 S L20 NOT PY>=1997

FILE 'EPFULL, FRFULL, GBFULL, PATDPAFULL, PCTFULL, RDISCLOSURE,  
USPATFULL, USPAT2' ENTERED AT 14:27:39 ON 11 MAY 2005

L22 3256 S L12  
L23 15 S L22 NOT PY>1997  
L24 15 DUP REM L23 (0 DUPLICATES REMOVED)

=>

L24 ANSWER 8 OF 15 PCTFULL COPYRIGHT 2005 Univentio on STN

ACCESSION NUMBER: 1996034943 PCTFULL ED 20020514

TITLE (ENGLISH): HUMAN LEUKOCYTE 12-LIPOXYGENASE AND ITS ROLE IN THE  
PATHOGENESIS OF DISEASE STATES

TITLE (FRENCH): 12-LIPOXYGENASE LEUCOCYTAIRE HUMAINE ET SON ROLE DANS  
LA PATHOGENESE D'ETATS PATHOLOGIQUES

INVENTOR(S): NADLER, Jerry, L.;  
NATARAJAN, Rama

PATENT ASSIGNEE(S): CITY OF HOPE;  
NADLER, Jerry, L.;  
NATARAJAN, Rama

LANGUAGE OF PUBL.: English

DOCUMENT TYPE: Patent

PATENT INFORMATION:

NUMBER	KIND	DATE
-----		
WO 9634943	A1	19961107

DESIGNATED STATES

W: AU CA JP US AT BE CH DE DK ES FI FR GB GR IE IT LU MC  
NL PT SE

APPLICATION INFO.: WO 1996-US6328 A 19960503

PRIORITY INFO.: US 1995-8/434,681 19950504

=> d ibib 1-5

L9 ANSWER 1 OF 5 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN  
ACCESSION NUMBER: 1996:506788 BIOSIS  
DOCUMENT NUMBER: PREV199699229144  
TITLE: The insulin-sensitizing agent troglitazone improves  
metabolic and reproductive abnormalities in the polycystic  
ovary syndrome.  
AUTHOR(S): Dunaif, Andrea [Reprint author]; Scott, Denise; Finegood,  
Diane; Quintana, Benjamin; Whitcomb, Randall  
CORPORATE SOURCE: Dep. Med., Melton S. Hershey Med. Cent., 500 University  
Dr., Room C-6630, Hershey, PA 17033-0850, USA  
SOURCE: Journal of Clinical Endocrinology and Metabolism, (1996)  
Vol. 81, No. 9, pp. 3299-3306.  
CODEN: JCEMAZ. ISSN: 0021-972X.  
DOCUMENT TYPE: Article  
LANGUAGE: English  
ENTRY DATE: Entered STN: 14 Nov 1996  
Last Updated on STN: 14 Nov 1996

L9 ANSWER 2 OF 5 BIOSIS COPYRIGHT (c) 2005 The Thomson Corporation on STN  
ACCESSION NUMBER: 1996:197933 BIOSIS  
DOCUMENT NUMBER: PREV199698754062  
TITLE: The thiazolidinedione drug series.  
AUTHOR(S): Stevenson, Ralph W. [Reprint author]; Gibbs, E. Michael;  
Kreutter, David K.; McPherson, R. Kirk; Clark, David A.;  
Hulin, Bernard; Goldstein, Steven W.; Parker, Janice C.;  
Swick, Andrew G.; Treadway, Judith; Hargrove, Diane M.;  
Shulman, Gerald I.  
CORPORATE SOURCE: Dep. Metab. Dis., Central Res. Div., Pfizer Inc., Eastern  
Point Road, Groton, CT 06340, USA  
SOURCE: Marshall, S. M. [Editor]; Home, P. D. [Editor]; Rizza, R.  
A. [Editor]. Diabetes Annual, (1995) pp. 175-191. Diabetes  
Annual.  
Publisher: Elsevier Science Publishers B.V., PO Box 211,  
Sara Burgerhartstraat 25, 1000 AE Amsterdam, Netherlands;  
Elsevier Science Publishing Co., Inc., P.O. Box 882,  
Madison Square Station, New York, New York 10159-2101, USA.  
Series: Diabetes Annual.  
ISSN: 0168-9282. ISBN: 0-444-82055-8.  
DOCUMENT TYPE: Book  
Book; (Book Chapter)  
General Review; (Literature Review)  
LANGUAGE: English  
ENTRY DATE: Entered STN: 2 May 1996  
Last Updated on STN: 2 May 1996

L9 ANSWER 3 OF 5 MEDLINE on STN DUPLICATE 1  
ACCESSION NUMBER: 95203206 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 7895657  
TITLE: Antidiabetic thiazolidinediones block the inhibitory effect  
of tumor necrosis factor-alpha on differentiation,  
insulin-stimulated glucose uptake, and gene expression in  
3T3-L1 cells.  
AUTHOR: Szalkowski D; White-Carrington S; Berger J; Zhang B  
CORPORATE SOURCE: Department of Molecular Endocrinology, Merck Research  
Laboratories, Rahway, New Jersey 07065.  
SOURCE: Endocrinology, (1995 Apr) 136 (4) 1474-81.  
Journal code: 0375040. ISSN: 0013-7227.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals  
ENTRY MONTH: 199504  
ENTRY DATE: Entered STN: 19950504  
Last Updated on STN: 19950504  
Entered Medline: 19950425

L9 ANSWER 4 OF 5 MEDLINE on STN DUPLICATE 2  
ACCESSION NUMBER: 95045256 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 7956951  
TITLE: Troglitazone prevents the inhibitory effects of  
inflammatory cytokines on insulin-induced adipocyte  
differentiation in 3T3-L1 cells.  
AUTHOR: Ohsumi J; Sakakibara S; Yamaguchi J; Miyadai K; Yoshioka S;  
Fujiwara T; Horikoshi H; Serizawa N  
CORPORATE SOURCE: Biomedical Research Laboratories, Sankyo Co. Ltd., Tokyo,  
Japan.  
SOURCE: Endocrinology, (1994 Nov) 135 (5) 2279-82.  
Journal code: 0375040. ISSN: 0013-7227.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals  
ENTRY MONTH: 199412  
ENTRY DATE: Entered STN: 19950110  
Last Updated on STN: 19950110  
Entered Medline: 19941216

L9 ANSWER 5 OF 5 MEDLINE on STN DUPLICATE 3  
ACCESSION NUMBER: 94102197 MEDLINE  
DOCUMENT NUMBER: PubMed ID: 8275942  
TITLE: Altered gene expression for tumor necrosis factor-alpha and  
its receptors during drug and dietary modulation of insulin  
resistance.  
AUTHOR: Hofmann C; Lorenz K; Braithwaite S S; Colca J R; Palazuk B  
J; Hotamisligil G S; Spiegelman B M  
CORPORATE SOURCE: Research Service, Hines Veterans Administration Hospital,  
Illinois 60141.  
SOURCE: Endocrinology, (1994 Jan) 134 (1) 264-70.  
Journal code: 0375040. ISSN: 0013-7227.  
PUB. COUNTRY: United States  
DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
LANGUAGE: English  
FILE SEGMENT: Abridged Index Medicus Journals; Priority Journals  
ENTRY MONTH: 199402  
ENTRY DATE: Entered STN: 19940218  
Last Updated on STN: 19940218  
Entered Medline: 19940207

ACCESSION NUMBER: 95:141561 PROMT  
TITLE: Atorvastatin Superior To Other Statins?  
SOURCE: Marketletter, (24 Apr 1995) pp. N/A.  
ISSN: 0140-4288.  
LANGUAGE: English  
WORD COUNT: 267

\*FULL TEXT IS AVAILABLE IN THE ALL FORMAT\*

AB Parke-Davis' HMG-CoA reductase inhibitor atorvastatin has outperformed other statin drugs in head-to-head comparative studies, according to company chairman Ronald Cresswell at an analysts' briefing in New York, USA.

Atorvastatin, at a dose of 10mg, is more effective in reducing serum lipids than all the other available statins at their highest approved doses, said Dr Cresswell. The drug lowers low-density lipoprotein cholesterol by as much as 60%, triglycerides by as much as 40%, and raises beneficial high-density lipoprotein cholesterol by around 12%.

Dr Cresswell predicted that a New Drug Application for atorvastatin would be filed in the middle of next year, and the company hopes to achieve sales of \$800 million a year at peak. The company expects to build on the lipid -lowering franchise it has achieved with its Lopid (gemfibrozil) range of products.

Pipeline Prospects Also highlighted at the briefing was a new diabetes therapy, troglitazone, which has an NDA submission scheduled for December 1996. Parke-Davis parent company Warner-Lambert licenses this drug from Japan's Sankyo, while Glaxo holds European rights. The three companies are sharing clinical data. Dr Cresswell noted that the drug appears to lower insulin resistance without impairing gluconeogenesis in the liver. Peak North American sales have been estimated at \$400 million, according to the company.

THIS IS AN EXCERPT: Copyright 1995 Marketletter (Publications) Ltd.

ACCESSION NUMBER: 1997:2622 CAPLUS

DOCUMENT NUMBER: 126:54540

TITLE: Chemoprevention of mammary **carcinoma** by  
LGD1069 (**Targretin**): an RXR-selective ligand  
AUTHOR(S): Gottardis, Marco M.; Bischoff, Eric D.; Shirley,  
Michael A.; Wagoner, Murriel A.; Lamph, William W.;  
Heyman, Richard A.

CORPORATE SOURCE: Dep. Endocrine Res., Ligand Pharm., Inc., San Diego,  
CA, 92121, USA

SOURCE: Cancer Research (1996), 56(24), 5566-5570  
CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB To explore the specific contribution that retinoid X-receptor (RXR) activation may play in suppression of **carcinogenesis**, the efficacy of LGD1069 (**Targretin**), an RXR-selective ligand, in the N-nitroso-N-methylurea-induced rat mammary **tumor** model was studied. LGD1069-treated animals showed a 90% reduction in **tumor** burden and **tumor** incidence compared with vehicle-treated rats, a drug efficacy similar to that achieved with tamoxifen. LGD1069 was very well tolerated during 13 wk of chronic therapy, with no classic signs of retinoid-associated toxicities. Thus, LGD1069, an RXR-selective ligand, can act as a highly effective and benign chemopreventive agent for mammary **carcinoma**.